Coverage for tirzepatide tracks the indication written on the prescription far more than the molecule in the vial. Diabetes is covered widely, documented sleep apnoea increasingly, chronic weight management least often — and compounded preparations effectively not at all.
Pick your situation to see what applies and what to ask for. This is general guidance on how coverage works, not a determination about your plan; only your plan document and your insurer can give you that.
Why indication decides it
Plans cover conditions, not molecules. The same tirzepatide is routinely covered as Mounjaro for diabetes and excluded as Zepbound for weight management by the same insurer.
Exclusion versus denial
A denial can be appealed on medical necessity. A categorical exclusion is plan design and cannot. Knowing which you face saves weeks — the answer is in your plan document, not the denial letter.
If you are moving to cash
Price the market before your last covered fill rather than after. Interruption is what undoes results, and the gap between routes is wide enough that many people who stop for cost did not need to.
Frequently asked questions
Does Medicare cover Zepbound now?
The Medicare GLP-1 Bridge began dispensing on 1 July 2026 at a flat $50/month for eligible Part D beneficiaries; for tirzepatide only the Zepbound KwikPen is included. Verify with your plan.
Will insurance cover compounded tirzepatide?
Almost never. Treat compounded routes as a cash market and check HSA/FSA eligibility instead.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.